Erleada

Active substance

Holder

Status

Closed

Indication

In combination with androgen deprivation therapy (ADT) for the treatment of adult patients having castration resistant prostate cancer with PSADT ≤ 10 months and no detected metastases using imaging as per physician’s clinical practice

Public documents

Approbation

Information for the patient

Informed consent

Last update

31/08/2021